Sponsor Pipeline

Trevi Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
3
Recruiting
1
Phase 3
1
Disease Areas
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-11 NCT07671924
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With…		 Trial sites expanded: 5 -> 10 locations
2026-08-04 NCT07036029
NAL ER IPF Respiratory Function and Safety Study		 Trial completed
2026-08-04 NCT07036029
NAL ER IPF Respiratory Function and Safety Study		 Enrollment reduced: 10 -> 9 participants
Active Trials by Phase
Phase 3
1
Phase 2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07671911 Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine… Idiopathic Pulmonary Fibrosis Recruiting
Phase 2
NCT07671924 The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With… Refractory Chronic Cough Recruiting
Phase 1
NCT07487740 A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine… Healthy Participants Recruiting
Disease Areas
Idiopathic Pulmonary Fibrosis (1)
Get alerts when Trevi Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free